Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285802125> ?p ?o ?g. }
- W4285802125 endingPage "1142" @default.
- W4285802125 startingPage "1142" @default.
- W4285802125 abstract "The COVID-19 pandemic emerged in 2020 and has caused an unprecedented burden to all countries in the world. SARS-CoV-2 continues to circulate and antigenically evolve, enabling multiple reinfections. To address the issue of the virus antigenic variability, T cell-based vaccines are being developed, which are directed to more conserved viral epitopes. We used live attenuated influenza vaccine (LAIV) virus vector to generate recombinant influenza viruses expressing various T-cell epitopes of SARS-CoV-2 from either neuraminidase (NA) or non-structural (NS1) genes, via the P2A self-cleavage site. Intranasal immunization of human leukocyte antigen-A*0201 (HLA-A2.1) transgenic mice with these recombinant viruses did not result in significant SARS-CoV-2-specific T-cell responses, due to the immunodominance of NP366 influenza T-cell epitope. However, side-by-side stimulation of peripheral blood mononuclear cells (PBMCs) of COVID-19 convalescents with recombinant viruses and LAIV vector demonstrated activation of memory T cells in samples stimulated with LAIV/SARS-CoV-2, but not LAIV alone. Hamsters immunized with a selected LAIV/SARS-CoV-2 prototype were protected against challenge with influenza virus and a high dose of SARS-CoV-2 of Wuhan and Delta lineages, which was confirmed by reduced weight loss, milder clinical symptoms and less pronounced histopathological signs of SARS-CoV-2 infection in the lungs, compared to LAIV- and mock-immunized animals. Overall, LAIV is a promising platform for the development of a bivalent vaccine against influenza and SARS-CoV-2." @default.
- W4285802125 created "2022-07-19" @default.
- W4285802125 creator A5003302132 @default.
- W4285802125 creator A5004325493 @default.
- W4285802125 creator A5010790842 @default.
- W4285802125 creator A5018605826 @default.
- W4285802125 creator A5019174664 @default.
- W4285802125 creator A5025015981 @default.
- W4285802125 creator A5044164358 @default.
- W4285802125 creator A5047402800 @default.
- W4285802125 creator A5048412868 @default.
- W4285802125 creator A5059564579 @default.
- W4285802125 creator A5073267913 @default.
- W4285802125 creator A5074265719 @default.
- W4285802125 creator A5075128188 @default.
- W4285802125 creator A5082475492 @default.
- W4285802125 creator A5091717802 @default.
- W4285802125 date "2022-07-18" @default.
- W4285802125 modified "2023-09-27" @default.
- W4285802125 title "Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector" @default.
- W4285802125 cites W1963492502 @default.
- W4285802125 cites W1966829335 @default.
- W4285802125 cites W1973077339 @default.
- W4285802125 cites W2004482125 @default.
- W4285802125 cites W2007747470 @default.
- W4285802125 cites W2011386800 @default.
- W4285802125 cites W2047688749 @default.
- W4285802125 cites W2077640158 @default.
- W4285802125 cites W2100509873 @default.
- W4285802125 cites W2116640473 @default.
- W4285802125 cites W2129056107 @default.
- W4285802125 cites W2168274979 @default.
- W4285802125 cites W2192165606 @default.
- W4285802125 cites W2292472819 @default.
- W4285802125 cites W2615853094 @default.
- W4285802125 cites W2884942225 @default.
- W4285802125 cites W2898556596 @default.
- W4285802125 cites W2928550480 @default.
- W4285802125 cites W2944340404 @default.
- W4285802125 cites W2954376662 @default.
- W4285802125 cites W2996762750 @default.
- W4285802125 cites W3001118548 @default.
- W4285802125 cites W3001897055 @default.
- W4285802125 cites W3038131143 @default.
- W4285802125 cites W3042183476 @default.
- W4285802125 cites W3043559115 @default.
- W4285802125 cites W3045033340 @default.
- W4285802125 cites W3047159181 @default.
- W4285802125 cites W3047483639 @default.
- W4285802125 cites W3048775784 @default.
- W4285802125 cites W3101669111 @default.
- W4285802125 cites W3103140952 @default.
- W4285802125 cites W3113621889 @default.
- W4285802125 cites W3122458452 @default.
- W4285802125 cites W3133277826 @default.
- W4285802125 cites W3139922556 @default.
- W4285802125 cites W3157646192 @default.
- W4285802125 cites W3160504045 @default.
- W4285802125 cites W3163785571 @default.
- W4285802125 cites W3175747586 @default.
- W4285802125 cites W3175941513 @default.
- W4285802125 cites W3175976364 @default.
- W4285802125 cites W3176171025 @default.
- W4285802125 cites W3176494753 @default.
- W4285802125 cites W3178327581 @default.
- W4285802125 cites W3183895649 @default.
- W4285802125 cites W3185109960 @default.
- W4285802125 cites W3187353105 @default.
- W4285802125 cites W3195795781 @default.
- W4285802125 cites W3196426448 @default.
- W4285802125 cites W3197781442 @default.
- W4285802125 cites W3198863342 @default.
- W4285802125 cites W3202455909 @default.
- W4285802125 cites W3209130765 @default.
- W4285802125 cites W3209923446 @default.
- W4285802125 cites W3211023780 @default.
- W4285802125 cites W3212840395 @default.
- W4285802125 cites W3215049942 @default.
- W4285802125 cites W4207047906 @default.
- W4285802125 cites W4210792795 @default.
- W4285802125 cites W4212956740 @default.
- W4285802125 cites W4213274436 @default.
- W4285802125 cites W4213450806 @default.
- W4285802125 cites W4214479284 @default.
- W4285802125 cites W4220860951 @default.
- W4285802125 cites W4224442169 @default.
- W4285802125 cites W4225282917 @default.
- W4285802125 cites W4225550167 @default.
- W4285802125 cites W4226051990 @default.
- W4285802125 cites W4280594901 @default.
- W4285802125 cites W4281561106 @default.
- W4285802125 cites W3017952584 @default.
- W4285802125 doi "https://doi.org/10.3390/vaccines10071142" @default.
- W4285802125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35891306" @default.
- W4285802125 hasPublicationYear "2022" @default.
- W4285802125 type Work @default.
- W4285802125 citedByCount "6" @default.
- W4285802125 countsByYear W42858021252022 @default.